长沙晚报掌上长沙2月19日讯（全媒体记者 徐媛）近日，湖南省医保局印发《湖南省城乡居民高血压糖 尿病门诊用药范围及医保支付标准（2026版）》，结合国家医保药品目录（2025年）调整情况，进一步 优化湖南省城乡居民高血压、糖尿病（以下简称"两病"）门诊用药保障政策，建立科学规范的用药范围 和支付标准动态调整机制，切实减轻参保患者用药负担，保障用药需求。 用药范围进一步拓宽，两类核心药品全覆盖 此次政策调整以2025年版"两病"门诊用药范围及支付标准为基础，严格对照《国家基本医疗保险、工伤 保险和生育保险药品目录（2025年）》，将两类关键药品全部纳入"两病"门诊用药范围。 其中，对西药部分、协议期内谈判药品两个部分中高血压用药（药品分类代码XC02抗高血压药、XC03 利尿剂、XC07/XC07Aβ-受体阻滞剂、XC08钙通道阻滞剂、XC09作用于肾素-血管紧张素系统的药 物）、糖尿病用药（药品分类代码XA10），全部纳入两病用药范围，进一步拓宽了参保患者的用药选 择。 动态调整"两病"门诊用药范围，持续优化服务 在医保支付标准方面，湖南省严格按照国家相关规定，对国家谈判及集采范围内的"两病"药品支付标准 进 ...

Core Viewpoint - Algeria's government is enhancing its pharmaceutical industry by establishing new production facilities in the southern provinces to achieve self-sufficiency and ensure national drug supply [1] Group 1: New Production Facilities - The state-owned pharmaceutical group Saidal will build new drug production plants in the southern provinces of Ouled Djellal, Ouargla, and Tamanrasset [1] - The new factories aim to decentralize production and better meet regional demands while strengthening industrial development in the south [1] Group 2: Economic and Employment Impact - The initiative is expected to create job opportunities and promote economic development in the inland and southern provinces [1] - Collaboration with the Algerian Investment Promotion Agency will support the development of pharmaceutical projects utilizing local land resources [1] Group 3: Local Production Goals - Plans include the local production of key pharmaceutical raw materials, covering diabetes medications, cancer drugs, heart disease treatments, and antibiotics [1] - Some strategic projects are anticipated to commence production by the end of 2026, with local production of dental anesthetics starting next year to address supply shortages [1] Group 4: Overall Objectives - The overarching goals are to enhance the autonomy of the pharmaceutical industry, reduce reliance on imports, ensure drug supply, and promote balanced economic development across regions [1]

Core Viewpoint - The eleventh batch of national organized drug procurement is set to officially announce its selection results, with new rules focusing on stabilizing clinical use, ensuring quality, preventing excessive competition, and avoiding collusion, thereby fostering a healthy environment for the pharmaceutical industry [1] Group 1: Selection Results and Impact - The results of the eleventh batch of drug procurement will be officially announced, with patients expected to access a new batch of quality and affordable drugs by February 2026 [1] - A total of 272 companies with 55 varieties and 453 products have obtained proposed selection qualifications, increasing the total number of drug varieties included in national procurement to 490 [1] - Over 70% of the reported quantities were successful, with mainstream companies that have strong supply capabilities and quality assurance mostly selected [2] Group 2: New Rules and Quality Control - The new procurement rules emphasize quality control, raising the quality threshold for companies and requiring that selected drugs have no quality issues in the past two years [2][3] - The introduction of a "reference price" mechanism aims to prevent extreme low pricing and encourages rational bidding among companies [4][5] - The procurement process has seen a significant increase in competition, with some products having up to 48 companies competing, indicating a robust supply capacity in the pharmaceutical industry [7] Group 3: Industry Challenges and Future Directions - The industry faces challenges related to low profit margins for selected drugs, which may lead to concerns about quality and sustainability in the long term [6] - Experts suggest that the "anti-involution" measures should not only focus on procurement but also guide companies in scientific project initiation to avoid excessive competition in the same drug category [8]